source Post navigation SGLT2 Inhibitors in T2DM Linked to Lower GI Cancer Risk – Medscape Biolexis Therapeutics launches subsidiary Metabolexis to develop novel oral medicines for Obesity and Type 2 Diabetes to improve human longevity – Yahoo Finance